Vaccines with aluminum-containing adjuvants: Optimizing vaccine efficacy and thermal stability

Journal of Pharmaceutical Sciences

Volumn 100, Issue 2, 2011, Pages 388-401

  Clapp, Tanya ^a   Siebert, Paul ^a   Chen, Dexiang ^b   Jones Braun, LaToya ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b PATH   (United States)

Author keywords

Adsorption; Formulation; Particle size; Physicochemical properties; Protein structure; Stability; Vaccine adjuvants; Vaccines

Indexed keywords

ALUMINUM; ANTHRAX VACCINE; DIPHTHERIA TETANUS TOXOID; IMMUNOLOGICAL ADJUVANT; RECOMBINANT HEPATITIS B VACCINE; VACCINE;

ADSORPTION; ARTICLE; DRUG EFFICACY; IMMUNOGENICITY; THERMOSTABILITY;

EID: 78650555727     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22284     Document Type: Article

References (71)

1. Glenny A, Pope C, Waddington H, Wallace U. 1926. The antigenic value of toxoid precipitated by potassium alum. J Pathol Bacteriol 29:38-45.
2. Glenny A, Buttle G, Stevens M. 1931. Rate of disappearance of diphtheria toxoid injected into rabbits and guinea-pigs: Toxoid precipitated with alum. J Pathol Bacteriol 34:267-275.
3. Marrack P, McKee AS, Munks MW. 2009. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 9(4):287-293.
4. McKee AS, Munks MW, Marrack P. 2007. How do adjuvants work? Important considerations for new generation adjuvants. Immunity 27(5):687-690.
5. Hem SL, Hogenesch H. 2007. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev Vaccines 6(5):685-698.
6. Aimanianda V, Haensler J, Lacroix-Desmazes S, Kaveri SV, Bayry J. 2009. Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants. Trends Pharmacol Sci 30(6):287-295.
7. Lambrecht BN, Kool M, Willart MA, Hammad H. 2009. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 21(1):23-29.
8. De Gregorio E, D'Oro U, Wack A. 2009. Immunology of TLR-independent vaccine adjuvants. Curr Opin Immunol 21(3):339-345.
9. Sokolovska A, Hem SL, HogenEsch H. 2007. Activation of dendritic cells and induction of CD4(+) T cell differentiation by aluminum-containing adjuvants. Vaccine 25(23):4575-4585.
10. Korsholm KS, Petersen RV, Agger EM, Andersen P. 2010. T-helper 1 and T-helper 2 adjuvants induce distinct differences in the magnitude, quality and kinetics of the early inflammatory response at the site of injection. Immunology 129(1):75-86.
11. Li H, Nookala S, Re F. 2007. Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release. J Immunol 178(8):5271-5276.
12. Franchi L, Nunez G. 2008. The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity. Eur J Immunol 38(8):2085-2089.
13. Kool M, Soullie T, van Nimwegen M, Willart MA, Muskens F, Jung S, Hoogsteden HC, Hammad H, Lambrecht BN. 2008. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 205(4):869-882.
14. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. 2008. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453(7198):1122-1126.
15. Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL, Fitzgerald KA, Latz E. 2008. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 9(8):847-856.
16. Li H, Ambade A, Re F. 2009. Cutting edge: Necrosis activates the NLRP3 inflammasome. J Immunol 183(3):1528-1532.
17. Hansen B, Sokolovska A, HogenEsch H, Hem SL. 2007. Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response. Vaccine 25(36):6618-6624.
18. World Health Organization. 1977. Manual for production and control of vaccines-tetanus toxoid. Geneva: World Health Organization.
19. GlaxoSmithKline. 2009. Engerix-B [hepatitis B vaccine (recombinant)] prescribing information. GlaxoSmithKlineBiologicals, Rixensart, Belgium, US License No. 1617.
20. Chang M, Shi Y, Nail SL, HogenEsch H, Adams SB, White JL, Hem SL. 2001. Degree of antigen adsorption in the vaccine or interstitial fluid and its effect on the antibody response in rabbits. Vaccine 19(20-22):2884-2889.
21. Clausi A, Cummiskey J, Merkley S, Carpenter JF, Braun LJ, Randolph TW. 2008. Influence of particle size and antigen binding on effectiveness of aluminum salt adjuvants in a model lysozyme vaccine. J Pharm Sci 97(12):5252-5262.
22. Berthold I, Pombo ML, Wagner L, Arciniega JL. 2005. Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants. Vaccine 23(16):1993-1999.
23. Romero Mendez IZ, Shi Y, HogenEsch H, Hem SL. 2007. Potentiation of the immune response to non-adsorbed antigens by aluminum-containing adjuvants. Vaccine 25(5):825-833.
24. Levesque PM, Foster K, de Alwis U. 2006. Association between immunogenicity and adsorption of a recombinant Streptococcus pneumoniae vaccine antigen by an aluminum adjuvant. Hum Vaccin 2(2):74-77.
25. Iyer S, HogenEsch H, Hem SL. 2003. Relationship between the degree of antigen adsorption to aluminum hydroxide adjuvant in interstitial fluid and antibody production. Vaccine 21(11-12):1219-1223.
26. Morefield GL, Jiang D, Romero-Mendez IZ, Geahlen RL, Hogenesch H, Hem SL. 2005. Effect of phosphorylation of ovalbumin on adsorption by aluminum-containing adjuvants and elution upon exposure to interstitial fluid. Vaccine 23(12):1502-1506.
27. Morefield GL, Sokolovska A, Jiang D, HogenEsch H, Robinson JP, Hem SL. 2005. Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 23(13):1588-1595.
28. Egan PM, Belfast MT, Gimenez JA, Sitrin RD, Mancinelli RJ. 2009. Relationship between tightness of binding and immunogenicity in an aluminum-containing adjuvant-adsorbed hepatitis B vaccine. Vaccine 27(24):3175-3180.
29. Hansen B, Belfast M, Soung G, Song L, Egan PM, Capen R, Hogenesch H, Mancinelli R, Hem SL. 2009. Effect of the strength of adsorption of hepatitis B surface antigen to aluminum hydroxide adjuvant on the immune response. Vaccine 27(6):888-892.
30. Lin L, Ibrahim AS, Avanesian V, Edwards JE Jr, Fu Y, Baquir B, Taub R, Spellberg B. 2008. Considerable differences in vaccine immunogenicities and efficacies related to the diluent used for aluminum hydroxide adjuvant. Clin Vaccine Immunol 15(3):582-584.
31. Wittayanukulluk A, Jiang D, Regnier FE, Hem SL. 2004. Effect of microenvironment pH of aluminum hydroxide adjuvant on the chemical stability of adsorbed antigen. Vaccine 22(9-10):1172-1176.
32. Estey T, Vessely C, Randolph TW, Henderson I, Braun LJ, Nayar R, Carpenter JF. 2009. Evaluation of chemical degradation of a trivalent recombinant protein vaccine against botulinum neurotoxin by LysC peptide mapping and MALDI-TOF mass spectrometry. J Pharm Sci 98(9):2994-3012.
33. Tleugabulova D, Falcon V, Penton E. 1998. Evidence for the denaturation of recombinant hepatitis B surface antigen on aluminium hydroxide gel. J Chromatogr B Biomed Sci Appl 720(1-2):153-163.
34. Jones LS, Peek LJ, Power J, Markham A, Yazzie B, Middaugh CR. 2005. Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens. J Biol Chem 280(14):13406-13414.
35. Zheng Y, Lai X, Ipsen H, Larsen JN, Lowenstein H, Songergaard I, Jacobsen S. 2007. Structural changes of protein antigens due to adsorption onto and release from aluminum hydroxide using FTIR-ATR. Spectroscopy 21:211-226.
36. Dong A, Jones LS, Kerwin BA, Krishnan S, Carpenter JF. 2006. Secondary structures of proteins adsorbed onto aluminum hydroxide: Infrared spectroscopic analysis of proteins from low solution concentrations. Anal Biochem 351(2):282-289.
37. Agopian A, Ronzon F, Sauzeat E, Sodoyer R, El Habib R, Buchet R, Chevalier M. 2007. Secondary structure analysis of HIV-1-gp41 in solution and adsorbed to aluminum hydroxide by Fourier transform infrared spectroscopy. Biochim Biophys Acta 1774(3):351-358.
38. Peek LJ, Martin TT, Elk Nation C, Pegram SA, Middaugh CR. 2007. Effects of stabilizers on the destabilization of proteins upon adsorption to aluminum salt adjuvants. J Pharm Sci 96(3):547-557.
39. Vessely C, Estey T, Randolph TW, Henderson I, Cooper J, Nayar R, Braun LJ, Carpenter JF. 2009. Stability of a trivalent recombinant protein vaccine formulation against botulinum neurotoxin during storage in aqueous solution. J Pharm Sci 98(9):2970-2993.
40. Bai S, Dong A. 2009. Effects of immobilization onto aluminum hydroxide particles on the thermally induced conformational behavior of three model proteins. Int J Biol Macromol 45(1):80-85.
41. Zheng Y, Lai X, Ipsen H, Larsen JN, Lowenstein H, Songergaard I, Jacobsen S. 2007. The structural stability of protein antigens adsorbed by aluminum hydroxide in comparison to the antigens in solution. Spectroscopy 21:257-268.
42. Jezek J, Chen D, Watson L, Crawford J, Perkins S, Tyagi A, Jones-Braun L. 2009. A heat-stable hepatitis B vaccine formulation. Hum Vaccin 5(8):529-535.
43. Ausar SF, Espina M, Brock J, Thyagarayapuran N, Repetto R, Khandke L, Middaugh CR. 2007. High-throughput screening of stabilizers for respiratory syncytial virus: Identification of stabilizers and their effects on the conformational thermostability of viral particles. Hum Vaccin 3(3):94-103.
44. Salnikova MS, Joshi SB, Rytting JH, Warny M, Middaugh CR. 2008. Preformulation studies of Clostridium difficile toxoids A and B. J Pharm Sci 97(10):4194-4207.
45. Rexroad J, Evans RK, Middaugh CR. 2006. Effect of pH and ionic strength on the physical stability of adenovirus type 5. J Pharm Sci 95(2):237-247.
46. Peek LJ, Brey RN, Middaugh CR. 2007. A rapid, three-step process for the preformulation of a recombinant ricin toxin A-chain vaccine. J Pharm Sci 96(1):44-60.
47. Brandau DT, Joshi SB, Smalter AM, Kim S, Steadman B, Middaugh CR. 2007. Stability of the Clostridium botulinum type A neurotoxin complex: An empirical phase diagram based approach. Mol Pharm 4(4):571-582.
48. He F, Joshi SB, Bosman F, Verhaeghe M, Middaugh CR. 2009. Structural stability of hepatitis C virus envelope glycoprotein E1: Effect of pH and dissociative detergents. J Pharm Sci 98(9):3340-3357.
49. Peek LJ, Brandau DT, Jones LS, Joshi SB, Middaugh CR. 2006. A systematic approach to stabilizing EBA-175 RII-NG for use as a malaria vaccine. Vaccine 24(31-32):5839-5851.
50. Kueltzo LA, Ersoy B, Ralston JP, Middaugh CR. 2003. Derivative absorbance spectroscopy and protein phase diagrams as tools for comprehensive protein characterization: A bGCSF case study. J Pharm Sci 92(9):1805-1820.
51. Matthias DM, Robertson J, Garrison MM, Newland S, Nelson C. 2007. Freezing temperatures in the vaccine cold chain: A systematic literature review. Vaccine 25(20):3980-3986.
52. Chen D, Tyagi A, Carpenter J, Perkins S, Sylvester D, Guy M, Kristensen DD, Braun LJ. 2009. Characterization of the freeze sensitivity of a hepatitis B vaccine. Hum Vaccin 5(1):26-32.
53. Maa YF, Zhao L, Payne LG, Chen D. 2003. Stabilization of alum-adjuvanted vaccine dry powder formulations: Mechanism and application. J Pharm Sci 92(2):319-332.
54. Braun LJ, Jezek J, Peterson S, Tyagi A, Perkins S, Sylvester D, Guy M, Lal M, Priddy S, Plzak H, Kristensen D, Chen D. 2009. Characterization of a thermostable hepatitis B vaccine formulation. Vaccine 27(34):4609-4614.
55. Braun LJ, Tyagi A, Perkins S, Carpenter J, Sylvester D, Guy M, Kristensen D, Chen D. 2009. Development of a freeze-stable formulation for vaccines containing aluminum salt adjuvants. Vaccine 27(1):72-79.
56. Clausi AL, Merkley SA, Carpenter JF, Randolph TW. 2008. Inhibition of aggregation of aluminum hydroxide adjuvant during freezing and drying. J Pharm Sci 97(6):2049-2061.
57. Zapata MI, Feldkamp JR, Peck GE, White JL, Hem SL. 1984. Mechanism of freeze-thaw instability of aluminum hydroxycarbonate and magnesium hydroxide gels. J Pharm Sci 73(1):3-8.
58. Nygaard UC, Samuelsen M, Aase A, Lovik M. 2004. The capacity of particles to increase allergic sensitization is predicted by particle number and surface area, not by particle mass. Toxicol Sci 82(2):515-524.
59. Wolff L, Flemming J, Schmitz R, Gröger K, Müller-Goymann C. 2008. Protection of aluminum hydroxide during lyophilisation as an adjuvant for freeze-dried vaccines. Colloids Surf A Physicochem Eng Aspects 330(2-3):116-126.
60. Cape SP, Villa JA, Huang ET, Yang TH, Carpenter JF, Sievers RE. 2008. Preparation of active proteins, vaccines and pharmaceuticals as fine powders using supercritical or near-critical fluids. Pharm Res 25(9):1967-1990.
61. Sellers SP, Clark GS, Sievers RE, Carpenter JF. 2001. Dry powders of stable protein formulations from aqueous solutions prepared using supercritical CO(2)-assisted aerosolization. J Pharm Sci 90(6):785-797.
62. Sievers RE, Quinn BP, Cape SP, Searles JA, Braun CS, Bhagwat P, Rebits LG, McAdams DH, Burger JL, Best JA, Lindsay L, Hernandez MT, Kisich KO, Iacovangelo T, Chen. DKD. 2007. Near-critical fluid micronization of stabilized vaccines, antibiotics and anti-virals. J Supercrit Fluids 42:385-391.
63. Sievers RE, Karst U, Milewski PD, Sellers SP, Miles BA, Schaefer JD, Stoldt CR, Xu CY. 1999. Formation of aqueous small droplet aerosols assisted by supercritical carbon dioxide. Aerosol Sci Technol 30:3-15.
64. Burger JL, Cape SP, Braun CS, McAdams DH, Best JA, Bhagwat P, Pathak P, Rebits LG, Sievers RE. 2008. Stabilizing formulations for inhalable powders of live-attenuated measles virus vaccine. J Aerosol Med Pulm Drug Deliv 21(1):25-34.
65. Heimlich JM, Regnier FE, White JL, Hem SL. 1999. The in vitro displacement of adsorbed model antigens from aluminium-containing adjuvants by interstitial proteins. Vaccine 17(22):2873-2881.
66. Rinella JV Jr, White JL, Hem SL. 1996. Treatment of aluminium hydroxide adjuvant to optimize the adsorption of basic proteins. Vaccine 14(4):298-300.
67. Seeber SJ, White JL, Hem SL. 1991. Predicting the adsorption of proteins by aluminium-containing adjuvants. Vaccine 9(3):201-203.
68. al-Shakhshir RH, Regnier FE, White JL, Hem SL. 1995. Contribution of electrostatic and hydrophobic interactions to the adsorption of proteins by aluminium-containing adjuvants. Vaccine 13(1):41-44.
69. Iyer S, HogenEsch H, Hem SL. 2003. Effect of the degree of phosphate substitution in aluminum hydroxide adjuvant on the adsorption of phosphorylated proteins. Pharm Dev Technol 8(1):81-86.
70. Iyer S, Robinett RS, HogenEsch H, Hem SL. 2004. Mechanism of adsorption of hepatitis B surface antigen by aluminum hydroxide adjuvant. Vaccine 22(11-12):1475-1479.
71. Jendrek S, Little SF, Hem S, Mitra G, Giardina S. 2003. Evaluation of the compatibility of a second generation recombinant anthrax vaccine with aluminum-containing adjuvants. Vaccine 21(21-22):3011-3018.